[Urinary incontinence: new pharmacologic therapies].
Several classes of drugs have been investigated for their efficacy in treating overactive bladder syndrome (OAB) and stress urinary incontinence (SUI). Surgery and behavioral therapies are currently the mainstay of treating SUI. However, results are also being made available about a new oral medication, Duloxetine, which appears to be clinically safe and effective for the treatment of SUI. On the other hand, a new muscarinic receptor antagonist, Solifenacin, has been shown in clinical trials to be clinically effective, safe and well tolerated for treating OAB.
Robles García
J E
JE
Departamento de Urología, Clínica Universitaria, Facultad de Medicina, Universidad de Navarra. jerobles@unav.es
Zudaire Bergera
J J
JJ
Rosell Costa
D
D
Berián Polo
J M
JM
D000068736:Duloxetine Hydrochloride; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D011812:Quinuclidines / Q000627:therapeutic use; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D014549:Urinary Incontinence / Q000188:drug therapy*
D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D013876:Thiophenes; D000068736:Duloxetine Hydrochloride; D000069464:Solifenacin Succinate